Cardiovascular Disease (Heart Attacks and Strokes)
Kills More Men and Women in Australia
… than All Cancers Combined !! …
The Arginine – Citrulline and Nitric Oxide Story
Using this Simple and Safe Treatment Approach‚ You Can Now …
• Lower cholesterol
• Reduce blood pressure
• Increase energy levels and feelings of wellbeing
• Stabilise and then remove plaques lining the arteries
• Increase blood flow and oxygen to the brain and the entire body
• Restore the health, elasticity and function of all the arteries throughout the body
• Prevent and treat, heart attacks, strokes, heart rhythm problems, diabetic gangrene and neuropathy
Who Can Benefit from Arginine, Citrulline and Nitric Oxide Boosting?
• You, your family, your friends, your clients, athletes. In fact, everybody!
The full story is described in the movies on Arginine, Citrulline and Nitric Oxide
The movies by 4 brilliant doctors and researchers will give you some very important insights into the use of L-Arginine, L-Citrulline and Nitric Oxide in the treatment, prevention and reversal of Cardiovascular disease and Atherosclerosis throughout the body, as well as preventing heart attacks, strokes, diabetic gangrene and neuropathy.
The treatment also has a profoundly beneficial effect with many other conditions including Diabetes, Kidney disease, improves response to Cancer Treatments as well as speeding the recovery of those who have suffered Heart Attacks or Strokes and will greatly reduce the likelihood of a recurrence.
There are over 25 years of intensive medical research behind this treatment approach
In 1998 the Nobel Prize in Medicine was awarded to Dr Louis Ignarro together with Dr Robert Furchgott and Dr Ferid Murad for their discoveries relating to L Arginine, L Citrulline, Nitric Oxide cell signalling and Cardiovascular disease.
There has been continued research and development of the treatment cardiovascular disease using L Arginine, L Citrulline and Nitric Oxide boosting since 1998 to such a degree that it is now possible to reverse even extremely serious and advanced congestive heart failure and pulmonary hypertension.
Studies conducted at the High Desert Heart Institute in the USA by Dr Siva Arunsalam on 39 seriously ill heart patients have shown amazing results – Watch his movies to see the full story.
Whenever most doctors, specialists and professors comment in newspapers, magazines or on TV, about the use of nutritional medicine in the treatment of various diseases we often hear comments such as –
There is no real science behind the theories that nutrients can be used successfully in the treatment of serious diseases.
There have been no double blind, placebo-controlled studies supporting such claims etc. etc.
Such claims made by medical professionals untrained in nutrition and nutritional biochemistry are Uninformed and Misleading.
• The average medical professional spends approximately only 2 weeks learning about nutrition out of many years of study for their medical degrees and post-graduate qualifications.
• The average naturopath spends 4 years completing a university degree that includes anatomy, physiology, diet and lifestyle therapies, nutritional medicine, herbal medicine and nutritional biochemistry.
• However, the good news is that many more doctors are studying nutritional medicine post graduate to their medical degrees. These doctors are practicing integrative medicine that combines both traditional western medicine plus nutrition and nutritional biochemistry in their practices.
• The very successful approach proposed here in the treatment of heart and circulatory diseases is supported by no less than the Nobel Prize in Medicine that was presented to 3 medical researchers way back in 1998 !
• Out of the thousands of high quality medical studies and research projects that are conducted each year around the world, only one is judged to be of such importance to the health of mankind that the Nobel Prize is awarded to the scientists conducting the research.
• So as far as scientific validation goes … It doesn’t get any better than the Nobel Prize !!
Who is at risk of sudden death in Australia from a heart attack? Sudden cardiac arrest (SCA) — or massive heart attack — as it is sometimes known, which kills an estimated 33,000 people in Australia alone each year, can strike anyone. Even a seemingly healthy person can suffer cardiac arrest without warning. According to the American Heart Association® (AHA), as many as 50% of SCA victims have no prior indication of heart disease — their first symptom is cardiac arrest.
Nutrients required for the production of Nitric Oxide. Prolonging the life of Nitric Oxide in the body with the use of antioxidants. The many benefits of Nitric Oxide within the body. Increasing Nitric Oxide in the brain improves and restores memory anLouis J Ignarrod learning.
80 year old arteries at age 37 … 15 year old arteries at 72 years of age!. Joe used the results of the research he conducted together with three pharmacologists (who subsequently won the Nobel prize in medicine for their research on Nitric Oxide and its vital cell signalling properties) to create a treatment program for atherosclerosis and circulation restoration. Dr. Joe was able to reverse his own life threatening problem with atherosclerosis completely.
Nobel Prize Winners
Louis J Ignarro
Ferid Murad
Robert F. Furchgott
Serrapeptase, Nattokinase, Bromelain and Magnesium Orotate: Exploring Their Roles in Cardiovascular Support
Cardiovascular disease remains a leading global health challenge, driven by factors such as atherosclerosis, elevated blood pressure, impaired fibrinolysis, chronic inflammation and endothelial dysfunction. Certain proteolytic enzymes and mineral forms have attracted interest as complementary approaches. Four ingredients commonly combined in specialised formulas—serrapeptase, nattokinase, bromelain and magnesium orotate—are frequently discussed in this context. Below is an evidence-based overview of each and their potential relevance to heart and vascular health.
Nattokinase
Nattokinase is a serine protease derived from Bacillus subtilis fermentation of soybeans (natto). It is best known for its fibrinolytic activity: it directly degrades fibrin and can enhance the body’s own plasminogen-activator system.
Human studies have shown measurable effects on clotting markers and, in some cases, blood pressure and arterial measures. Randomised trials have reported modest reductions in systolic and diastolic blood pressure (typically in the range of 3–6 mmHg) with doses around 2,000 fibrinolytic units (FU). Higher-dose observational and open-label work (6,000–10,800 FU daily) has reported reductions in carotid intima-media thickness and plaque size, along with improvements in lipid profiles in some cohorts. A large 2022 study of over 1,000 participants using 10,800 FU daily observed meaningful decreases in carotid plaque metrics, while a lower dose (3,600 FU) was ineffective.
However, results are not uniform. A rigorous three-year randomised controlled trial using 2,000 FU in lower-risk individuals found no significant effect on subclinical atherosclerosis progression measured by carotid ultrasound. Overall, nattokinase shows the strongest clinical signal among the four ingredients for fibrinolysis and modest blood-pressure support, but dose, population risk level and study design appear critical.
Serrapeptase (Serratiopeptidase)
Serrapeptase is a bacterial metalloprotease with anti-inflammatory, anti-oedematous and proteolytic properties. Laboratory work demonstrates fibrinolytic and caseinolytic activity, which has led to marketing claims about clot and plaque dissolution.
High-quality clinical evidence for cardiovascular outcomes is lacking. Systematic reviews have concluded that existing studies are generally of poor methodological quality, with small sample sizes and limited relevance to atherosclerosis or major cardiac endpoints. While the enzyme is used in some countries for post-surgical swelling and certain inflammatory conditions, there are no robust randomised trials demonstrating meaningful reduction of arterial plaque or prevention of cardiovascular events in humans. Claims of “dissolving” atherosclerotic plaque remain unsupported by current clinical data.
Bromelain
Bromelain is a mixture of proteolytic enzymes from pineapple stems. It exhibits anti-inflammatory effects, can modulate certain cytokines, and has been shown in laboratory and animal models to support fibrinolysis and nitric-oxide pathways.
Recent mechanistic research indicates bromelain may increase nitric-oxide bioavailability via bradykinin-receptor and AMPK-related signalling, potentially supporting endothelial function and vasodilation. Animal studies also suggest anti-atherosclerotic and antioxidant effects through autophagy and reduced oxidative stress. Human data on cardiovascular endpoints remain limited; most clinical research focuses on inflammation, pain and post-surgical recovery rather than hard cardiac outcomes. Some older reports note effects on blood viscosity and platelet aggregation, but these require confirmation in larger modern trials.
Magnesium Orotate
Magnesium is essential for hundreds of enzymatic reactions, vascular smooth-muscle relaxation, electrical stability of the heart and blood-pressure regulation. Orotate is a carrier form that may enhance cellular uptake and has been studied specifically in cardiac contexts.
Meta-analyses and clinical trials of magnesium orotate have reported benefits in patients with heart failure, arrhythmias, mitral-valve prolapse and coronary disease. One controlled study in severe congestive heart failure found improved survival and symptom scores when magnesium orotate was added to standard therapy. Other work has shown improvements in exercise tolerance, left-ventricular parameters and reductions in certain inflammatory and remodelling markers. Magnesium deficiency itself is linked to higher cardiovascular risk, so correcting low levels is a rational goal; the orotate form has a longer clinical history in European cardiology practice than some other magnesium salts.
Potential Synergy and Practical Considerations
The combination is theoretically complementary: nattokinase and serrapeptase both support fibrinolysis (via somewhat different mechanisms), bromelain adds anti-inflammatory and nitric-oxide support, and magnesium orotate addresses mineral status and myocardial energetics. In practice, no large randomised trials have tested this exact four-ingredient stack for cardiovascular endpoints. Additive effects on fibrinolysis raise the possibility of increased bleeding risk, especially when combined with anticoagulant or antiplatelet medications.
Typical studied or product doses vary widely. Nattokinase efficacy appears dose-dependent in some datasets (higher FU amounts showing clearer vascular imaging changes). Serrapeptase doses in supplements are often modest relative to anti-inflammatory research ranges. Magnesium orotate elemental magnesium content is relatively low per capsule, so cumulative intake matters.
Safety and Caveats
All four ingredients are generally well tolerated in healthy adults at conventional supplemental doses, but important precautions apply:
Individuals on blood thinners, antiplatelet agents, or with bleeding disorders should avoid unsupervised use of nattokinase and serrapeptase.
Pre-surgical patients should discontinue fibrinolytic enzymes well in advance.
Magnesium supplementation requires caution in kidney impairment.
These ingredients are not substitutes for proven therapies (statins, antihypertensives, lifestyle measures, smoking cessation, etc.) that have robust outcome data.
Bottom Line
Nattokinase currently has the most substantial human evidence among the four for supporting fibrinolysis, modest blood-pressure reduction and, at higher doses, favourable changes in carotid plaque metrics. Magnesium orotate has supportive clinical data in heart-failure and arrhythmic contexts. Bromelain offers plausible anti-inflammatory and endothelial mechanisms, while serrapeptase’s cardiovascular claims remain largely theoretical. A combined approach may appeal as a complementary strategy, yet it should be viewed as experimental relative to guideline-directed care. Consultation with a qualified healthcare practitioner is essential before use, particularly for anyone with existing cardiovascular disease or on concurrent medications.
This article is for informational purposes only and does not constitute medical advice. Individual responses vary; always seek personalised guidance from a licensed healthcare professional.